Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, G. David Roodman, MD PhD, Larry D. Cripe, MD, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Katie J Sargent, RN, Hamid Sayar, MD MSc, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2019) 134 (Supplement_1): 5051.

https://doi.org/10.1182/blood-2019-124384

Published: 2019

Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2018) 132 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2018-99-111181

Published: 2018

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Blood (2018) 132 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2018-99-118383

Published: 2018

Journal Articles

Genomic Landscapes in Elderly AML

Blood (2017) 130 (Supplement 1): 404.

https://doi.org/10.1182/blood.V130.Suppl_1.404.404

Published: 2017

Journal Articles

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Antoine N Saliba, MD, H. Scott Boswell, MD, Larry D Cripe, MD, Mohammad Issam Abu Zaid, MBBS, Jill Weisenbach, RN, OCN, Hamid Sayar, MD MSc

Blood (2017) 130 (Supplement 1): 3897.

https://doi.org/10.1182/blood.V130.Suppl_1.3897.3897

Published: 2017

Journal Articles

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

Chezi Ganzel, Larry D. Cripe, MD, Zhouxin Sun, Hugo F. Fernandez, MD, Peter A Cassileth, MD, Dan Douer, MD, Jacob M. Rowe, MD, Elisabeth Paietta, PhD, Michael O'Connell, Peter H Wiernik, John M. Bennett, MD, Mark R Litzow, MD, Selina Luger, MD, Hillard M. Lazarus, MD, Martin S. Tallman, MD

Blood (2015) 126 (23): 1315.

https://doi.org/10.1182/blood.V126.23.1315.1315

Published: 2015

Journal Articles

The Combination of the Novel Syk Inhibitor TAK659 with Decitabine Exerts Synergistic Cytotoxic Effects Against FLT3/ITD Mutated Acute Myeloid Leukemia Cells

Edwin Stage, MS, Magdalena Czader, MD PhD, Heather O'Leary, PhD, H. Scott Boswell, MD, Larry D. Cripe, MD, Hamid Sayar, MD, Cedric Dos Santos, PhD, Mark J. Levis, MD PhD, Heiko Konig, MDPhD

Blood (2015) 126 (23): 4928.

https://doi.org/10.1182/blood.V126.23.4928.4928

Published: 2015

Journal Articles

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Monosomy 5, 7, or Complex Cytogenetics

Mohammad Abu Zaid, MBBS, H. Scott Boswell, MD, Larry D. Cripe, MD, Yan Liu, PhD, Jill Weisenbach, BS, Hamid Sayar, MD MS

Blood (2014) 124 (21): 976.

https://doi.org/10.1182/blood.V124.21.976.976

Published: 2014

Journal Articles

High-Risk AML, Including Flt3ITD+, Exhibits Resistance To Conventional Cytarabine Induction Associated With Diminished ENT1 and p16INK Expression: Evidence For Epigenetic Repression and HDAC Inhibitor Modulated De-Repression

H. Scott Boswell, MD, Sushil Gupta, Rui Gao, PhD, Katie J Sargent, Larry D. Cripe, MD, Mehdi Nassiri, MD, Hamid Sayar, MD, Yan Liu, PhD

Blood (2013) 122 (21): 2525.

https://doi.org/10.1182/blood.V122.21.2525.2525

Published: 2013

Journal Articles

Pilot Study Of Erlotinib In Patients With Acute Myeloid Leukemia

Hamid Sayar, MD, MSc, Magdalena Czader, MD, PhD, Chirag Amin, MD, Mary Cangany, Bsc, Larry D Cripe, MD

Blood (2013) 122 (21): 5037.

https://doi.org/10.1182/blood.V122.21.5037.5037

Published: 2013

Journal Articles

Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML

Blood (2012) 120 (21): 1875.

https://doi.org/10.1182/blood.V120.21.1875.1875

Published: 2012

Journal Articles

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

Alessandra Cesano, M.D., Ph.D., Cheryl L Willman, MD, Kenneth J. Kopecky, PhD, Urte Gayko, Ph.D., Santosh Putta, Ph.D., Brent Louie, Ph.D., Matt Westfall, Ph.D., Norman Purvis, Ph.D., David Spellmeyer, PhD, Carol Marimpietri, James Hackett, Ph.D., Jing Shi, Elisabeth Paietta, PhD, Martin S. Tallman, MD, Larry D Cripe, MD, Susan K. Atwater, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD

Blood (2012) 120 (21): 2489.

https://doi.org/10.1182/blood.V120.21.2489.2489

Published: 2012

Journal Articles

The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999

James M. Foran, MD, FRCPC, Zhuoxin Sun, PhD, Hugo F. Fernandez, MD, Larry D Cripe, MD, Rhett P Ketterling, MD, Janis Racevskis, PhD, Selina M. Luger, MD, Elisabeth Paietta, PhD, Hillard M. Lazarus, MD, FACP, Mark R. Litzow, MD, Martin S. Tallman, MD

Blood (2011) 118 (21): 2568.

https://doi.org/10.1182/blood.V118.21.2568.2568

Published: 2011

Journal Articles

Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status

Alessandra Cesano, M.D., Ph.D., Santosh Putta, Ph.D., Kavita Mathi, MD, David B. Rosen, PhD, Urte Gayko, Ph.D., Rachael E. Hawtin, Ph.D., Larry D Cripe, MD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Elisabeth Paietta, Ph.D.

Blood (2011) 118 (21): 2512.

https://doi.org/10.1182/blood.V118.21.2512.2512

Published: 2011

Journal Articles

Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7

Stephen A Strickland, MD, MSCI, Zhuoxin Sun, PhD, Rhett P Ketterling, MD, Athena M Cherry, PhD, Larry D Cripe, MD, Gordon Dewald, PhD, Rodney R Higgins, PhD, MS, Hillard M Lazarus, MD, Mark R Litzow, MD, Selina M Luger, MD, Elisabeth Paietta, PhD, Jacob M Rowe, MD, Hajime Uno, PhD, Gail H Vance, MD, Martin S Tallman, MD

Blood (2010) 116 (21): 579.

https://doi.org/10.1182/blood.V116.21.579.579

Published: 2010

Journal Articles

Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis.

Rajasubramaniam Shanmugam, PhD., Annique Wilson-Weekes, MS, Hamid Sayar, MD, Attaya Suvannasankha, MD, Angelo A. Cardoso, MD., PhD, Katie J Sargent, RN, Larry D. Cripe, MD, Dhananjaya V Kalvakolanu, PhD., H. Scott Boswell, MD

Blood (2009) 114 (22): 2387.

https://doi.org/10.1182/blood.V114.22.2387.2387

Published: 2009

Journal Articles

Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia.

Sherif Farag, MD, PhD, Lisa L Wood, RN, Jennifer E. Schwartz, MD, FRCP(C), Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Michael Robertson, MD, Rafat Abonour, MD, Hamid Sayar, MD, Larry D. Cripe, MD

Blood (2009) 114 (22): 198.

https://doi.org/10.1182/blood.V114.22.198.198

Published: 2009

Journal Articles

Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia.

Jeffrey Lancet, MD, Judith E. Karp, MD, Larry D. Cripe, MD, Gail J. Roboz, MD, Matt Suster, Nguyen Tan, Rachael Hawtin, Judith Fox, Craig Berman, Glenn Michelson

Blood (2008) 112 (11): 1955.

https://doi.org/10.1182/blood.V112.11.1955.1955

Published: 2008

Journal Articles

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Jonathan W. Friedberg, MD, Jeff Sharman, Julia Schaefer-Cutillo, Patrick B. Johnston, Sven De Vos, MD, PhD, Ann LaCasce, MD, John P. Leonard, MD, Larry D. Cripe, MD, Rajni Sinha, MD, Stephanie A. Gregory, John Sweetenham, Julie M. Vose, MD, Ann M Lowe, MD, R. Levy, Margaret A. Shipp, MD

Blood (2008) 112 (11): 3.

https://doi.org/10.1182/blood.V112.11.3.3

Published: 2008

Journal Articles

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Clemens M Wendtner, MD, Daruka Mahadevan, MD, PhD, Stephan Stilgenbauer, MD, PhD, Olga Frankfurt, MD, Adrian Bloor, PhD, MRCP, FRCPath, Francesc Bosch, MD, PhD, Lutz Uharek, Richard R Furman, MD, Marco Gobbi, John G. Gribben, MD, DSc, Eva K. Kimby, MD, PhD, Mikkael A. Sekeres, MD, MS, Larry D. Cripe, MD, Elyane Lombardy, Sheetal Shah, Laure A Moutouh-de Parseval, Asher Alban Chanan-Khan, MD, Robert D. Knight, MD

Blood (2008) 112 (11): 2104.

https://doi.org/10.1182/blood.V112.11.2104.2104

Published: 2008

NARROW

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Genomic Landscapes in Elderly AML

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

The Combination of the Novel Syk Inhibitor TAK659 with Decitabine Exerts Synergistic Cytotoxic Effects Against FLT3/ITD Mutated Acute Myeloid Leukemia Cells

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Monosomy 5, 7, or Complex Cytogenetics

High-Risk AML, Including Flt3ITD+, Exhibits Resistance To Conventional Cytarabine Induction Associated With Diminished ENT1 and p16INK Expression: Evidence For Epigenetic Repression and HDAC Inhibitor Modulated De-Repression

Pilot Study Of Erlotinib In Patients With Acute Myeloid Leukemia

Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999

Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status

Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7

Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis.

Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia.

Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia.

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only